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Abstract
Background: The 90-kDa ribosomal S6 kinase (Rsk) family is involved in cell survival. Rsk activation is regulated by
sequential phosphorylations controlled by extracellular signal-regulated kinase (ERK) 1/2 and 3-phosphoinositide-
dependent protein kinase 1 (PDK1). Altered ERK1/2 and PDK1 phosphorylation have been described in
Huntington’s disease (HD), characterized by the expression of mutant huntingtin (mhtt) and striatal degeneration.
However, the role of Rsk in this neurodegenerative disease remains unknown. Here, we analyzed the protein levels,
activity and role of Rsk in in vivo and in vitro HD models.
Results: We observed increased protein levels of Rsk1 and Rsk2 in the striatum of HdhQ111/Q111 and R6/1 mice,
STHdhQ111/Q111 cells and striatal cells transfected with full-length mhtt. Analysis of the phosphorylation of Rsk in
Hdh mice and STHdh cells showed reduced levels of phospho Ser-380 (dependent on ERK1/2), whereas
phosphorylation at Ser-221 (dependent on PDK1) was increased. Moreover, we found that elevated Rsk activity in
STHdhQ111/Q111 cells was mainly due to PDK1 activity, as assessed by transfection with Rsk mutant constructs. The
increase of Rsk in STHdhQ111/Q111 cells occurred in the cytosol and in the nucleus, which results in enhanced
phosphorylation of both cytosolic and nuclear Rsk targets. Finally, pharmacological inhibition of Rsk, knock-down
and overexpression experiments indicated that Rsk activity exerts a protective effect against mhtt-induced cell
death in STHdhQ7/Q7 cells transfected with mhtt.
Conclusion: The increase of Rsk levels and activity would act as a compensatory mechanism with capacity to
prevent mhtt-mediated cell death. We propose Rsk as a good target for neuroprotective therapies in HD.
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Background
The 90-kDa ribosomal S6 kinase (Rsk) is a family con-
stituted by four isoforms (Rsk1-4) of serine/threonine
kinases broadly expressed in the brain that regulate
important cellular functions, including cell survival [1].
Rsk is activated by extracellular signal-regulated protein
kinase (ERK) 1/2 [2] and 3-phosphoinositide-dependent
protein kinase 1 (PDK1) [3] by sequential phosphoryla-
tions in the C-terminal kinase domain (CTKD) and N-
terminal kinase domain (NTKD) [1,4], respectively.
Briefly, sequential phosphorylations are initiated by
ERK1/2 at Thr-573/574 of CTKD leading to the auto-
phosphorylation of Rsk at Ser-380. This phosphorylation
allows the dockage of PDK1 to the hydrophobic motif
and enables PDK1-dependent phosphorylation in the
NTKD of Rsk at Ser-221, resulting in its maximal acti-
vation [1,4]. When activated, Rsk promotes the phos-
phorylation of many cytosolic and nuclear targets. In
the cytosol, Rsk induces the inactivation of certain pro-
apoptotic proteins, such as Bad [5], glycogen synthase
kinase 3b (GSK-3b) [6] or death-associated protein
kinase (DAPK) [7], whereas in the nucleus it activates
transcription factors involved in the synthesis of anti-
apoptotic proteins, namely cAMP response element
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binding protein (CREB) [8], serum response factor (SRF)
[9], and IBa [10,11]. Although the function and the
mechanism of Rsk activation have been well studied in
non-neural cells, in neurons there are few studies about
Rsk, and they associate its activity with the anti-apopto-
tic effect of trophic factors [12-14]. However, no data
exists about the possible role of Rsk in neurodegenera-
tive diseases.
Huntington’s disease (HD) is a neurodegenerative dis-
order caused by a dominantly heritable expansion of a
trinucleotide CAG repeat in the huntingtin (htt) gene
[15], and characterized by the preferential neurodegen-
eration of striatal medium-sized spiny neurons [16].
Although the brain areas affected by the disease are well
established, the mechanisms by which neural dysfunc-
tion and neurodegeneration occurs are not well defined
yet. Interestingly, previous data from a HD cellular
model show a de-regulation of both kinases that control
Rsk activity. Knock-in striatal cells expressing full-length
mutant huntingtin (mhtt) (STHdhQ111/Q111) show
increased levels of active PDK1 [17] and reduced levels
of ERK1/2 activity [18] compared with striatal cells
expressing wild-type htt (STHdhQ7/Q7). Moreover, sti-
mulation of these kinases and their pathways has been
proposed as good therapeutic approaches for HD
[19-21]. These results suggest a de-regulation of Rsk
activity in HD models and that modulation of its activity
could be a good therapeutic strategy. Therefore, here we
studied whether the protein levels and activity of Rsk1
and Rsk2, the two isoforms with higher expression levels
[1], are modified in the presence of mhtt. To this end,
we analyzed striatal protein levels and activity of Rsk in
knock-in mhtt mouse and cellular models. In addition,
we studied the contribution of ERK1/2 and PDK1 to the
activation of Rsk in the presence of mhtt. Finally, we
evaluated the potential protective role of Rsk against
mhtt toxicity.
Results
Rsk1 and Rsk2 protein levels are increased in knock-in
and R6/1 models of HD
First of all, we analyzed by western blot whether the
protein levels of the two major Rsk isoforms, Rsk1 and
Rsk2, were altered in the striatum of 6- and 10-month
old wild-type (HdhQ7/Q7) and mutant (HdhQ111/Q111)
knock-in mice. We observed elevated Rsk1 and Rsk2
protein levels in the striatum of HdhQ111/Q111 mice
compared to HdhQ7/Q7 mice at both ages (Figure 1A
and 1B). In addition, the levels of these proteins were
also augmented in striatal cells expressing full-length
mhtt (STHdhQ111/Q111) when compared to those in
wild-type cells (STHdhQ7/Q7; Figure 1C and 1D). These
changes in Rsk1 and Rsk2 protein levels were not
dependent on mhtt protein levels since we observed
increased levels in Hdh mouse striatum expressing simi-
lar levels of mhtt (Figure 1A and 1B; HdhQ7/Q7 mice:
100 ± 9.8%; HdhQ111/Q111 mice: 89 ± 10.3%; Student’s t-
test: p = 0.4164) and in STHdhQ111/Q111 cells, which
express lower levels of mhtt compared with STHdhQ7/
Q7 (Figure 1C and 1D; STHdhQ7/Q7 cells: 100 ± 11.6%;
STHdhQ111/Q111 cells: 36 ± 6.9%; Student’s t-test: p <
0.001).
To know whether increased Rsk1 and Rsk2 protein
levels also occur in exon-1 mhtt mice we analyzed by
western blot these proteins in the striatum of R6/1 mice
at 8- and 12-week of age, when they do not show motor
symptoms [22]. Similar to that observed in the striatum
of knock-in mice, R6/1 mouse striatum displayed higher
Rsk1 and Rsk2 levels compared to wild-type (WT) mice
at both ages (Figure 1E and 1F). Altogether, these
results indicate that an increase of Rsk1 and Rsk2 pro-
tein levels is an event that occurs in full-length and
exon-1 models of HD at presymptomatic stages. In addi-
tion, changes in Rsk1 and Rsk2 are not dependent on
mhtt levels since we observed a similar response in
striatal cells expressing low (STHdhQ111/Q111 cells), nor-
mal (knock-in mice striatum) or very high (R6/1 mouse
striatum) levels of mhtt.
Overexpression of full-length mhtt increases Rsk protein
levels
In order to confirm that increased levels of Rsk were
dependent on mhtt expression, we looked at the protein
levels of Rsk1 and Rsk2 in STHdhQ7/Q7 cells, M213 cells
and striatal primary neurons transfected with a plasmid
expressing full-length wild-type (FL-17Q htt) or mutant
(FL-75Q htt) htt. The quantification of Rsk1 and Rsk2
levels was performed by confocal microscopy due to the
low efficiency of transfection (15-20% approximately). In
all cell types examined, transfection with FL-75Q htt
increased Rsk1 and Rsk2 protein levels compared to
those registered in cells expressing FL-17Q htt (Figure
2), indicating that the increase in Rsk1 and Rsk2 protein
levels are due to the presence of mhtt.
Rsk phosphorylation in HD knock-in models: ERK-
dependent residues versus PDK1-dependent residues
To study whether the phosphorylation levels of Rsk
were altered by changes in total Rsk protein levels, we
analyzed its phosphorylation at Ser-380 (dependent on
ERK1/2) and at Ser-221 (dependent on PDK1), in the
striatum of 10-month old HdhQ7/Q7 and HdhQ111/Q111
mice. We detected reduced levels of phospho-Rsk (Ser-
380; reduction of 63 ± 13%; Figure 3A) and increased
levels of phospho-Rsk (Ser-221; increase of 190 ± 19%;
Figure 3A) in HdhQ111/Q111 respect to HdhQ7/Q7 mice.
Similar results were obtained in STHdhQ111/Q111 cells
(Figure 3B). These results indicate that in the presence
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Figure 1 Rsk levels are elevated in HD mouse and cellular models. Rsk1 (A, C and E) and Rsk2 (B, D and F) protein levels were analyzed by
western blot of protein extracts obtained from the striatum of 6- and 10-month old wild-type (HdhQ7/Q7) and knock-in (HdhQ111/Q111) mice (A
and B), from wild-type (STHdhQ7/Q7) and mutant (STHdhQ111/Q111) htt knock-in striatal cells (C and D), and from the striatum of 8- and 12-week
old WT and R6/1 mice (E and F). Htt protein levels were also analyzed by western blot in knock-in models (A-D). Results (mean ± SEM; n = 4-6)
represent the ratio between Rsk and actin levels obtained by densitometric analysis of western blot data, and are expressed as a percentage of
HdhQ7/Q7 levels at 6 months (A and B), as a percentage of protein levels in STHdhQ7/Q7 cells (C and D), or as a percentage of protein levels in
WT mice at 8 weeks (E and F). Data were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test (A, B, E and F) or by Student’s t-
test (C and D). *p < 0.05 and **p < 0.01 as compared with HdhQ7/Q7 mice (A and B), **p < 0.01 and ***p < 0.001 as compared with STHdhQ7/Q7
cells (C and D), and *p < 0.05 and **p < 0.01 as compared with WT mice (E and F). Representative immunoblots are presented.
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of mhtt the phosphorylation of Rsk at ERK- and PDK1-
dependent residues is altered in an opposite way.
STHdhQ111/Q111 cells show increased Rsk activity that is
mainly regulated by PDK1
Our next goal was to know whether increased Rsk1 and
Rsk2 protein and phosphorylation levels were associated
with elevated Rsk activity. To this end, we analyzed Rsk
activity in knock-in cells by using an in vitro activity
assay. We observed that Rsk activity was higher in
STHdhQ111/Q111 than in STHdhQ7/Q7 cells (270 ± 15%;
Figure 4A). Moreover, overexpression of Rsk by trans-
fection of HA-Rsk1 in STHdhQ7/Q7 cells increased Rsk
activity (STHdhQ7/Q7 cells: 100 ± 9%; STHdhQ7/Q7 +
HA-Rsk: 222 ± 13%; p < 0.0002; Student’s t-test) indi-
cating that one of the parameters that regulates Rsk
activity is its protein levels.
To address the importance of phosphorylation by ERK1/
2 and PDK1 on elevated Rsk activation in STHdhQ111/Q111
cells, we measured Rsk activity in knock-in cells trans-
fected with two mutant forms of Rsk: HA-RskT574A and
HA-RskS380E, which cannot be phosphorylated by ERK1/
2 and PDK1, respectively. Transfection with HA-
RskT574A or HA-RskS380E similarly reduced Rsk activity
in STHdhQ7/Q7 cells (reduction of 28% and 33% respec-
tively; Figure 4B). Interestingly, and supporting a main
Figure 2 Overexpression of full-length mhtt in striatal cells increases Rsk levels. (A) Representative photomicrographs of htt and Rsk2
immunoreactivity in STHdhQ7/Q7 cells and striatal primary cultures after transfection (48 hours and 24 hours, respectively) with full-length wild-
type (FL-17Q htt) or mutant (FL-75Q htt) htt. Closed arrows indicate transfected cells (cells expressing higher levels of htt) and open arrows
indicate non-transfected cells. Scale bar: 16 μm. (B) Graphs showing Rsk1 and Rsk2 protein levels measured in STHdhQ7/Q7 cells, M213 cells and
striatal primary cultures after transfection (48 hours for STHdhQ7/Q7 and M213 cells, and 24 hours for striatal primary cultures) with full-length
wild-type (FL-17Q htt) or mutant (FL-75Q htt) htt. Data were expressed in arbitrary units and are the mean ± SEM of three independent
experiments performed in triplicate. Data were analyzed by Student’s t-test. *p < 0.05; **p < 0.01 and ***p < 0.001 as compared with FL-17Q htt-
transfected cells.
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role for PDK1 in the increased Rsk activity observed in
STHdhQ111/Q111 cells, transfection with HA-RskS380E
induced a stronger decrease of Rsk activity (47%; Figure
4B) compared with the transfection with HA-RskT574A
(19%; Figure 4B). Note that co-transfection with both
mutant forms reduced the activity of Rsk only by 30-40%
probably because the efficiency of transfection was not
maximal (Figure 4B).
Rsk levels are increased in both cytosol and nucleus of
STHdhQ111/Q111 cells
Phosphorylated and activated Rsk can translocate from
the cytosol to the nucleus. In these compartments, it
regulates different targets [1]. Thus, we studied Rsk1
and Rsk2 levels in cytosolic and nuclear fractions of
knock-in cells by western blot. When compared with
control cells, STHdhQ111/Q111 cells displayed enhanced
levels of Rsk1 and Rsk2 in both compartments, with a
more pronounced effect in the nucleus (Figure 5A). To
confirm these data, we analyzed the localization of Rsk
by immunocytochemistry. We detected three different
patterns of expression: homogeneous expression, and
exclusive cytosolic or nuclear localization (Figure 5B).
Analysis of STHdhQ7/Q7 cells revealed a predominant
homogeneous distribution of Rsk1, whereas Rsk2 was
mainly located in the nucleus. In STHdhQ111/Q111 cells,
Figure 3 Different regulation of phospho-Rsk residues in HD knock-in mice and STHdhQ111/Q111 cells. Lysates from the striatum of 10-
month old wild-type (HdhQ7/Q7) and knock-in (HdhQ111/Q111) mice (A) or from wild-type (STHdhQ7/Q7) and mutant (STHdhQ111/Q111) htt knock-in
striatal cells (B) were subjected to western blot to analyze phosphor-Rsk (Ser-380; Ser-221), Rsk1, Rsk2 and tubulin protein levels. Results (mean ±
SEM; n = 4-6) represent the ratio between phospho-Rsk levels and Rsk1 plus Rsk2 levels obtained by densitometric analysis of western blot data,
and are expressed as a percentage of HdhQ7/Q7 (A) or STHdhQ7/Q7 (B) levels. Representative immunoblots are presented. All data were analyzed
by Student’s t-test. *p < 0.05, **p < 0.01 and ***p < 0.001 as compared with HdhQ7/Q7 mice (A) or STHdhQ7/Q7 cells (B).
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Rsk1 changed its distribution as it was located only in
the nucleus, while the nuclear expression of Rsk2 was
even more evident than in STHdhQ7/Q7 cells. Note that
we did not observe exclusive cytosolic localization of
either Rsk isoforms in STHdhQ111/Q111 cells (Figure 5B).
Altogether, these results indicate that although the
increase of Rsk protein levels in STHdhQ111/Q111 cells
occurs in both compartments, this increase is more pro-
nounced in the nucleus.
Increased activity of Rsk in STHdhQ111/Q111 cells enhances
the phosphorylation of both cytosolic and nuclear targets
Rsk plays its protective role through the inactivation of
cytosolic pro-apoptotic proteins and/or the activation of
transcription factors that mediate the synthesis of anti-
apoptotic proteins. Thus, we determined in knock-in
cells expressing wild-type or mhtt the phospho-levels of
two Rsk substrates, Bad at Ser-112 (cytosolic target),
and SRF at Ser-103 (nuclear target). According with the
elevated Rsk activity observed in STHdhQ111/Q111 cells,
we found increased levels of phospho-Bad (Figure 6A)
and phospho-SRF (Figure 6B) respect to STHdhQ7/Q7
cells. Then, to determine whether the increased phos-
phorylation of Bad and SRF was due to the action of
Rsk, we treated knock-in cells with a pharmacological
and specific inhibitor of Rsk, BI-D1870 (0.1 μM) [23].
The presence of BI-D1870 reduced the phosphorylation
levels of both Bad and SRF in STHdhQ111/Q111 cells (Fig-
ure 6A and 6B). In STHdhQ7/Q7 cells, we did not
observe changes in phospho-Bad levels in the presence
of BI-D1870 (Figure 6A), whereas phospho-SRF levels
were slightly decreased (Figure 6B). To corroborate that
BI-D1870 efficiently inhibited Rsk, we tested the activity
of Rsk in both cell lines after treatment with Rsk inhibi-
tor. Addition of BI-D1870 (0.1 μM) completely inhibited
Rsk activity in STHdh cells (STHdhQ7/Q7 cells: 100 ±
14%; STHdhQ7/Q7 + BI: 7 ± 3%; STHdhQ111/Q111 cells:
286 ± 22%; STHdhQ111/Q111 + BI: 13 ± 5%). These
results show that increased Rsk activity in STHdhQ111/
Q111 cells results in augmented phosphorylation of both
cytosolic and nuclear targets.
Increased Rsk activity contributes to prevent mhtt-
induced cell death
To evaluate whether elevated Rsk activity could exert a
protective effect against mhtt-induced cell death, we
study its protective capacity against mhtt-induced toxi-
city using pharmacological inhibition, knock-down and
overexpression approaches. The expression of endogen-
ous mhtt in immortalized STHdhQ111/Q111 cells does not
Figure 4 Increased Rsk activity in STHdhQ111/Q111 cells is mainly regulated by PDK1. (A) Lysates from STHdhQ7/Q7 and STHdhQ111/Q111 cells
were subjected to immunoprecipitation with anti-Rsk1 and anti-Rsk2 antibodies and the resulting immunocomplexes were used to determine
Rsk activity as indicated in material and methods. Kinase activity was expressed as percentage of Rsk activity in STHdhQ7/Q7 cells and data are
the mean ± SEM of three independent experiments. Results were analyzed by Student’s t-test. **p < 0.01 as compared with STHdhQ7/Q7 cells. (B)
STHdhQ7/Q7 and STHdhQ111/Q111 cells were transfected with the following constructs: HA-RskT574A (to study the role of ERK1/2 on Rsk activity)
and HA-RskS380E (to analyze the role of PDK1 on Rsk activity). Twenty-four hours after transfection, both STHdhQ7/Q7 and STHdhQ111/Q111 cells
were subjected to Rsk activity assay. Results are the mean ± SEM of three independent experiments and are expressed as percentage of control
cells (cells transfected with HA alone). Data were analyzed by two-way ANOVA followed by Bonferroni’s post hoc test. **p < 0.01 and ***p <
0.001 as compared with STHdhQ7/Q7 control cells, +p < 0.05 and+++p < 0.001 as compared with STHdhQ111/Q111 control cells and#p < 0.05 as
compared with STHdhQ111/Q111 cells transfected with HA-Rsk T574A.
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Figure 5 Striatal cells expressing full-length mhtt show increased levels of Rsk in nuclear and cytosolic compartments. (A) Rsk1, Rsk2,
tubulin and NeuN were analyzed by western blot in cytosolic and nuclear fractions of STHdhQ7/Q7 and STHdhQ111/Q111 cells. Four independent
experiments were performed in duplicate. Representative immunoblots are shown. We quantified the levels of Rsk1 and Rsk2 in both types of
cells and analyzed the ratio between the nuclear and the cytosolic levels for each case. Data were analyzed by two-way ANOVA followed by
Bonferroni’s post hoc test. *p < 0.05 as compared with STHdhQ7/Q7 cells. (B) Representative photomicrographs showing Rsk1 and Rsk2
immunoreactivity in STHdhQ7/Q7 and STHdhQ111/Q111 cells. The number of cells was quantified according to three different patterns of Rsk1 and
Rsk2 localization: homogeneous localization (cytosolic and nuclear), exclusive cytosolic and exclusive nuclear localization. Nuclear localization was
determined by co-staining with Hoechst 33258. Results are expressed as percentage of total cell number. Data was analyzed by chi-square (c2).
For Rsk1; c square df: 102.5, 2 and p < 0.001. For Rsk2: c square df: 38.11, 2 and p < 0.001.
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produce cell death. Thus, to induce mhtt toxicity,
STHdhQ7/Q7 cells were transfected with wild-type (FL-
17Q htt) or mutant (FL-75Q htt) htt and cell death was
assessed by Hoechst 33258 staining 72 hours after trans-
fection. Overexpression of FL-75Q htt induced 16 ± 3%
apoptotic cell death versus 6 ± 2% apoptotic cell death
observed in FL-17Q htt-transfected cells (Figure 7A). In
parallel experiments we treated transfected cells with
the Rsk inhibitor BI-D1870 (0.1 μM). The inhibition of
Rsk exacerbated the toxic effect of FL-75Q htt expres-
sion and increased apoptotic cell death to 28 ± 4% (Fig-
ure 7A). In contrast, addition of BI-D1870 to FL-17Q
htt-transfected cells did not alter cell death (Figure 7A).
Our next goal was to know whether the protective role
of Rsk was mediated by Rsk1, Rsk2, or by both isoforms.
To address this issue, STHdhQ7/Q7 cells were co-trans-
fected with FL-75Q htt and with siRNAs against Rsk1
(siRsk1), Rsk2 (siRsk2) or both (siRsk1 + siRsk2). First,
we checked that transfection with siRsk1 or siRsk2 sepa-
rately decreased the protein levels of each isoform, and
that the co-transfection with siRsk1 and siRsk2 reduced
the expression of both isoforms (Figure 7B). The analy-
sis of cell death showed that inhibition of Rsk1 or Rsk2
separately was not enough to increase the toxic effect of
mhtt (Figure 7C). In contrast, the knock-down of both
isoforms enhanced FL-75Q htt-mediated cell death (Fig-
ure 7C), similar to that observed after treatment with
BI-D1870 (Figure 7A). To confirm the beneficial effect
of Rsk in cells expressing mhtt, we overexpressed Rsk in
cells transfected with FL-75Q htt by the co-transfection
with HA-Rsk. The analysis of cell death 72 hours later
revealed that Rsk overexpression reduced two-fold the
cell death induced by mhtt (Figure 7D). Thus, we con-
clude that Rsk activity exerts a protective effect against
mhtt-induced toxicity, and that both Rsk1 and Rsk2 iso-
forms are involved in this protective effect.
Discussion
In this work, we provide for the first time evidence for a
role of Rsk in HD. Within Rsk family, we analyzed Rsk1
and Rsk2, two isoforms that are broadly expressed in
the brain, including the striatum, and whose expression
levels are higher respect to other Rsk isoforms [1]. We
observed increased protein levels of both Rsk1 and Rsk2
in the striatum of HdhQ111/Q111 and R6/1 mice, and in
STHdhQ111/Q111 cells, which are not dependent on mhtt
protein levels as these HD models express different
levels of mhtt. Thus, increased Rsk1 and Rsk2 protein
levels is the result of the presence of mhtt, and we con-
firmed this hypothesis by showing that transfection of
FL-75Q htt in STHdhQ7/Q7 cells, M213 cells or striatal
primary cultures elevated the levels of both Rsk iso-
forms. In addition, increased Rsk1-2 protein levels cor-
related with higher basal Rsk activity in STHdhQ111/Q111
cells than in cells expressing wild-type htt. Interestingly,
the inhibition of Rsk activity enhanced striatal cell death
Figure 6 Inhibition of Rsk induces a reduction of pBAD and pSRF levels in STHdhQ111/Q111 cells. Lysates from STHdhQ7/Q7 and STHdhQ111/
Q111 cells treated with or without BI-D1870 (0.1 μM; BI) were subjected to western blot to analyze pBAD (Ser-112)/Bad (A) and pSRF (Ser-103)/
SRF (B) and tubulin protein levels. Results are expressed as the ratio between phospho and total Bad (A) and SRF (B) levels. Data are the mean ±
SEM of four independent experiments performed in duplicate. Representative immunoblots are presented. Results are expressed in percentage
respect to STHdhQ7/Q7 cells. Data were analyzed using two-way ANOVA followed by Bonferroni’s post hoc test. *p < 0.05 and **p < 0.01 as
compared with control STHdhQ7/Q7 cells and+++p < 0.001 as compared with control STHdhQ111/Q111 cells.
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Figure 7 Rsk protects against mhtt-induced cell death in striatal cells. (A) STHdhQ7/Q7 cells were transfected with full-length wild-type (FL-
17Q htt) or mutant (FL-75Q htt) htt and then treated with the Rsk inhibitor BI-D1870 (0.1 μM; BI). Cell death was determined 72 hours after
transfection using Hoechst 33258 staining and analyzing the condensation of the nucleus in transfected cells (cells expressing higher levels of
htt). Representative photomicrographs show apoptotic nuclei in each condition. (B) STHdhQ7/Q7 cells were transfected with siCT, siRsk1, siRsk2 or
siRsk1+siRsk2. Cells were lysed 72 hours after transfection and the levels of Rsk1, Rsk2 and tubulin were analyzed by western blot. (C) STHdhQ7/Q7
cells were co-transfected with FL-75Q htt and siCT, siRsk1, siRsk2 or siRsk1+siRsk2. Cell death was determined 72 hours after transfection using
Hoechst 33258 staining. (D) STHdhQ7/Q7 cells were co-transfected with FL-75Q htt and HA or HA-Rsk to study cell death 72 hours later using
Hoechst 33258 staining. Inset, A representative western blot showing the overexpression of Rsk 72 hours after transfection of STHdhQ7/Q7 cells
with HA-Rsk. In all cases, results are shown as percentage of apoptotic nuclei versus total nuclei and are the mean ± SEM of three independent
experiments performed in duplicate. Data were analyzed using two-way ANOVA followed by Bonferroni’s post hoc test (A and C) and using a
non-parametric t-test. In (A) *p < 0.05 as compared with FL-17Q htt-transfected cells and+p < 0.05 as compared with FL-75Q htt-transfected cells
without BI-D1870 treatment; in (C) *p < 0.05 as compared with cells transfected with FL-75Q htt and siCT and in (D) *p < 0.05 as compared with
cells transfected with FL-75Q htt and HA.
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induced by transfection of mhtt (FL-75Q htt) in
STHdhQ7/Q7 cells. Moreover, we show that the overex-
pression of Rsk reduces considerably cell death in
STHdhQ7/Q7 cells transfected with FL-75Q htt. Alto-
gether, these results indicate that elevated Rsk1-2 activ-
ity is an efficient mechanism to protect cells against
mhtt toxicity. Thus, increased activity of Rsk1-2 could
be a compensatory mechanism occurring in HD
striatum.
Compensatory responses activated at early phases of
HD are considered interesting targets to design neuro-
protective therapies to inhibit the progression of neuro-
degeneration. Here, we analyzed HdhQ111/Q111 mice at 6
and 10 months of age, and R6/1 at 8 and 12 weeks of
age, when they do not show motor dysfunction, but
express cellular and molecular markers of HD pathology
[22,24-28]. In addition, we studied the activity and the
neuroprotective role of Rsk in STHdh cells, which derive
from HdhQ111/Q111 embryos [29], and reproduce early
events in the disease cascade [17]. We observed that
increased Rsk activity is neuroprotective against mhtt-
induced cell death since inhibition of its activity in FL-
75Q htt-transfected STHdhQ7/Q7 cells increased cell
death. Moreover, we determined that this neuroprotec-
tive effect is due to an increase of Rsk activity in striatal
cells expressing mhtt, since the inhibition of Rsk did not
affect the viability of FL-17Q htt-transfected STHdhQ7/
Q7 cells. Confirming the protective role of Rsk against
mhtt, we overexpressed Rsk in STHdhQ7/Q7 cells and
showed a protective effect against mhtt-mediated cell
death. In addition, we show that both Rsk1 and Rsk2
are necessary to exert this protective role. Different stu-
dies in HD models have shown the regulation of other
kinases as compensatory mechanisms activated in
response of mhtt toxicity. These include Akt [17,30,31]
and proteins closely related to Akt, such as the serum-
and glucocorticoid-induced kinase [32]. Here, we show
that in addition to these kinases, Rsk activity is also up-
regulated in the presence of mhtt, and more impor-
tantly, that Rsk activity is neuroprotective against mhtt-
induced cell death.
Present results also show that the increased activity of
Rsk in striatal neurons expressing mhtt is mainly due to
the action of PDK1, a kinase whose activity is indepen-
dent of extracellular factors [3]. We detected increased
phosphorylation of Rsk at Ser-221 (dependent on PDK1)
and reduced phosphorylation of Rsk at Ser-380 (indir-
ectly dependent on ERK1/2) in HdhQ111/Q111 mice stria-
tum and STHdhQ111/Q111 cells. In accordance with our
results, STHdhQ111/Q111 cells display elevated levels of
phospho-PDK1 [17] and reduced levels of phospho-
ERK1/2 [18] respect to STHdhQ7/Q7 cells. In addition,
using mutant forms of Rsk, we show that the activity of
Rsk in STHdhQ111/Q111 cells was considerably inhibited
when PDK1-regulated, but not when ERK1/2-regulated
residues, were mutated. Consistent with our observa-
tions, it has been suggested that PDK1 has the capacity
to activate Rsk in an ERK1/2-independent manner [33].
Furthermore, and supporting the important role of
PDK1-mediated phosphorylation to Rsk activity, PDK1
deficiency results in Rsk inactivation [34]. Although the
neuroprotective role of Rsk has been classically asso-
ciated with extracellular stimuli induced by trophic fac-
tors such as brain-derived neurotrophic factor [13] or
epidermal growth factor [12] through the activation of
ERK1/2, Rsk phosphorylation by PDK1 increases its
activity to a higher extend than ERK1/2-dependent
phosphorylation [3]. In HD, neurotrophic deprivation
has been proposed as one of the mechanisms involved
in the preferential loss of striatal neurons [28,35,36].
Thus, in the absence of trophic support, activation of
Rsk through the basal activity of PDK1 could be a cru-
cial mechanism to prevent cell death in HD.
The neuroprotective activity of Rsk is basically due to
the wide range of proteins that it regulates. In the
nucleus, Rsk phosphorylates and activates several tran-
scription factors, some of them implicated in neuronal
survival such as SRF [9], CREB [37] or NFB [10,11].
Studies in non-neural cell lines showed that in the cyto-
sol Rsk phosphorylates and inactivates pro-apoptotic
proteins such as Bad [5], GSK-3b [6] or DAPK [7]. In
this way, our data indicate that Rsk1-2 activity is ele-
vated in the cytosol and in the nucleus of STHdhQ111/
Q111 cells. In the cytosol, increased Rsk activity corre-
lated with an enhancement of phosphorylated Bad,
whereas in the nucleus we observed increased levels of
phospho-SRF. Changes in phospho-Bad and phospho-
SRF were due, at least in part, to Rsk activation, since
inhibition of Rsk significantly reduced the phosphoryla-
tion levels of both proteins in STHdhQ111/Q111 cells. In
STHdhQ7/Q7 cells, the inhibition of Rsk produced a
slight effect on SRF phosphorylation levels, and we did
not detect an effect on Bad phosphorylation. Probably,
this lack of effect on Bad phosphorylation is due the
predominant nuclear activity of Rsk in unstimulated
cells [1,2]. Overall, we propose that the neuroprotective
effect of Rsk observed in the models studied here could
be mediated by the inactivation of pro-apoptotic factors
in addition to the activation of transcription factors that
regulate the expression of anti-apoptotic proteins.
Conclusions
In conclusion, here we provide evidences that the
increase of Rsk1-2 levels is an early event taking place
in striatal cells expressing full-length mhtt. Increased
Rsk1-2 levels contribute to enhance Rsk activity. Inter-
estingly, our results strongly support that increased Rsk
activity in the presence of mhtt is mainly regulated by
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the basal activity of PDK1 and not by ERK1/2. More-
over, we show that the increase of Rsk1-2 activity
observed in cells expressing mhtt could contribute to
prevent mhtt-induced cell death. This is the first work
showing a role for Rsk in HD, and we propose that
therapies targeted to maintain Rsk activity would be a
good approach for neuroprotection in HD.
Methods
HD mouse models
Homozygous mutant HdhQ111/Q111 and wild-type
HdhQ7/Q7 knock-in mice were obtained from mating
between male and female HdhQ111/Q7 heterozygotes as
described previously [23]. We also used R6/1 mice
(B6CBA background) expressing the exon-1 of mhtt
with 145 CAG repeats [38]. Mouse genotype was deter-
mined as described elsewhere [22]. CAG repeat length
was determined by PCR amplification of the repeat
using HD1 and HD2 fluorescently labeled primers as
previously describe by the Huntington’s Disease Colla-
borative Research Group [15], and subsequent size
determination in an ABI 3100 analyzer. These results
were double checked by Laragen, Inc. (Los Angeles,
CA). All mice used in the present study were housed
together in numerical birth order in groups of mixed
genotypes, and data were recorded for analysis by
microchip mouse number. Experiments were conducted
in a blind-coded manner respect to genotype. Mice were
genotyped by polymerase chain reaction as described
previously [23]. The animals were housed with access to
food and water ad libitum in a colony room kept at 19-
22°C and 40-60% humidity, under a 12:12 hours light/
dark cycle. All procedures were performed in compli-
ance with the National Institutes of Health Guide for
the Care and Use of Laboratory Animals, and approved
by the Local Animal Care Committee of Universitat de
Barcelona (99/01), and Generalitat de Catalunya (99/
1094), in accordance with the Directive 86/609/EU of
the European Commission.
Cell cultures and pharmacological treatments
Conditionally immortalized striatal neuronal progenitor
cell lines expressing endogenous levels of wild-type
(STHdhQ7/Q7) or mutant (STHdhQ111/Q111) full-length
htt with 7 and 111 glutamines, respectively, have been
described elsewhere [26]. Cells were grown at 33°C in
Dulbecco’s modified Eagle’s medium (DMEM; Sigma
Chemical Co, St. Louis, MO) supplemented with 10%
fetal bovine serum, 1% non-essential amino acids, 2 mM
L-glutamine, and 400 μg/ml G418 (Geneticin; Invitro-
gen, Carlsbad, CA). M213 cells (conditionally immorta-
lized striatal-derived neural stem cells) were grown as
previously described [39]. Primary striatal cultures were
obtained from 18-day old C57BL6 mouse embryos
(Charles River, France). Striata were dissected as pre-
viously described [40,41]. Cells (50,000 cells/cm2) were
seeded on plates pre-coated with 0.1 mg/mL poly-D-
lysine (Sigma Chemical Co.) and cultured in Neurobasal
medium supplemented with B27 (Gibco, Paisley, Scot-
land, UK) and glutamax at 37°C in a humidified atmo-
sphere containing 5% CO2.
To measure Rsk activity and phosphorylated levels of
Bad and SRF, the Rsk inhibitor BI-D1870 (0.1 μM,
Boehringer Ingelheim Pharma GmbH & Co) was added
during 4 hours to STHdhQ7/Q7 and STHdhQ111/Q111 cell
cultures. For quantification of apoptosis, STHdhQ7/Q7
and STHdhQ111/Q111 cells were treated with BI-D1870
(0.1 μM) for 72 hours.
DNA constructs and transfection
Full-length wild-type (FL-17Q htt) and mutant (FL-75Q
htt) htt constructs were a gift from Drs. Fréderic Saudou
and Sandrine Humbert (Institut Curie, Orsay, France).
HA-Rsk, HA-Rsk T574A and HA-Rsk S381E were
kindly provided by Dr. Dario Alessi (MRC Protein Phos-
phorylation Unit, Dundee, Scotland, UK). All DNA con-
structs were transfected using Lipofectamine 2000
(Invitrogen) as instructed by the manufacturer. Both
STHdhQ7/Q7 and M213 cells were transfected at 50%
confluence, whereas primary striatal cultures were trans-
fected at 5 days in vitro.
STHdhQ7/Q7 cells were transfected using 7.5 pmol
Rsk1 siRNA (Silencer® Pre-designed siRNA, s73163 and
s73164, Ambion, Applied Biosystems, Foster City, CA)
and/or Rsk2 siRNA (Silencer® Pre-designed siRNA,
s99855 and s99857, Ambion) with Lipofectamine 2000
as instructed by the manufacturer and incubated during
4 hours. A non-targeting control siRNA (7.5 pmol)
(Silencer® Negative Control 1 siRNA, Ambion) was
used to assess non-specific gene silencing effects. Cells
were lysed or fixed 72 hours after transfection.
Protein extraction and subcellular fractionation
STHdhQ7/Q7 and STHdhQ111/Q111 cells, with or without
BI-D1870 treatment or Rsk knock-down, were washed
once with phosphate-buffered saline (PBS), and total cel-
lular proteins were extracted by incubating cells in lysis
buffer containing 1% Triton X-100, 50 mM Tris-HCl
(pH 7.5), 10 mM EGTA, 150 mM NaCl, protease inhibi-
tors (2 mM phenylmethylsulfonyl fluoride (PMSF), 10
μg/μL aprotinin, 1 μg/μL leupeptin) and phosphatase
inhibitor sodium orthovanadate (2 mM). HdhQ7/Q7 and
HdhQ111/Q111 mice were deeply anesthetized and killed
by decapitation at the age of 6 and 10 months and wt
and R6/1 mice at 8 and 12 weeks of age. The brain was
quickly removed and the striatum was dissected out and
homogenized in lysis buffer (as above). All samples were
centrifuged at 16 100 × g for 20 minutes at 4°C, the
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supernatants were collected and protein concentration
was measured using the Dc protein assay kit (Bio-Rad
Laboratories, Hercules, CA).
For subcellular fractionation, STHdhQ7/Q7 and
STHdhQ111/Q111 cells were rinsed once with PBS and
centrifuged at 800 g for 5 minutes. Pellets were homoge-
nized in lysis buffer (10 mM Tris-HCl pH 7.5, 0.25 M
sucrose, 2 mM PMSF, 10 μg/μL aprotinin, 1 μg/μL leu-
peptin, 2 mM sodium orthovanadate) and centrifuged at
3000 × g for 10 minutes. The resulting supernatant was
centrifuged at 10 000 × g for 15 minutes to obtain a
cytosol/light membrane supernatant that was further
centrifuged at 100 000 × g for 15 minutes to obtain the
cytosolic fraction (supernatant). The pellet resulting
from the initial centrifugation was resuspended in lysis
buffer and centrifuged at 800 × g for 10 minutes. The
pellet, containing washed nuclear fraction, was then
resuspended in lysis buffer (50 mM Tris-HCl pH 7.5,
150 mM NaCl, 10% glycerol, 1% Triton X-100, 10 mM
EGTA, 2 mM PMSF, 10 μg/μL aprotinin, 1 μg/μL leu-
peptin, 2 mM sodium orthovanadate) and incubated for
30 minutes at 4°C in a tube rotator. Finally, after centri-
fuging for 15 minutes at 16 100 × g, the supernatant
was collected and stored. Protein concentrations were
determined as above.
Western blot
Western blot was performed as described elsewhere
[41]. The following primary antibodies were used: anti-
Rsk1, anti-Rsk2, anti-phospho-Rsk (Ser-221) and anti-
phospho-Rsk (Ser-380) (all 1:500; Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-htt monoclonal 2166
(1:1000; Millipore Bioscience Research reagents, Teme-
cula, CA), anti-phospho-SRF (Ser-103), anti-SRF, anti-
phospho-Bad (Ser-112) and anti-Bad (all 1:1000; Cell
Signaling Technology, Beverly, MA), and anti-HA
(1:1000; Sigma-Aldrich, Saint Louis, MO). Loading con-
trol was performed by reprobing the membranes with
anti-NeuN (1:1000; Chemicon, Temecula, CA), anti-a-
tubulin (1:100.000; Sigma-Aldrich) or anti-actin (1:10
000; MP Biochemicals, Aurora, OH).
Immunocytochemical staining, confocal microscopy
analysis, and Rsk localization
Cells were fixed in 4% paraformaldehyde for 10 minutes,
incubated with 0.2 M glycine for 20 minutes and per-
meabilized in 0.1% saponin for 10 minutes. Blocking
was performed with 1% BSA in PBS for 1 hour. Speci-
mens were incubated overnight with the primary antibo-
dies (all 1:100): anti-htt monoclonal 2166, anti-Rsk1 and
anti-Rsk2. Afterwards, specimens were incubated with
subtype-specific fluorescent secondary antibodies: Cya-
nine 3 anti-rabbit (1:200; Invitrogen), rhodamine-conju-
gated anti-mouse (1:200; Jackson ImmunoResearch,
West Grove, PA) and Alexa 647 anti-mouse (1:150;
Invitrogen).
For quantification of Rsk in htt-transfected cells,
immunocytochemistry was performed 24 (striatal pri-
mary cultures) or 48 (striatal knock-in and M213 cells)
hours after transfection. Quantification of Rsk1 and
Rsk2 was performed by confocal microscopy (Leica,
Mannheim, Germany) as previously described [42].
Values were expressed as a ratio between the sums of
Rsk1 or Rsk2 positive pixels versus cell area. For each
condition, 30-40 cells were randomly selected. To study
the localization of Rsk1 and Rsk2, STHdhQ7/Q7 and
STHdhQ111/Q111 cells were fixed at 80% confluence and
processed for immunocytochemistry against Rsk1 or
Rsk2. At least 250 cells were evaluated for each
condition.
Rsk activity assay
To measure Rsk activity, the assay was performed in
STHdh wild-type or mutant cells at 80% confluence or
24 hours after transfection with Rsk constructs, as
described previously [23]. Briefly, immunoprecipitation
of Rsk was performed by incubation of total protein
extracts (100 μg) with anti-Rsk1 and anti-Rsk2 antibo-
dies, 1 μg each. Then, immunoprecipitates were incu-
bated for 15 minutes at 30°C under continuous agitation
with the assay mixture buffer containing the substrate
peptide and the mixture of ATP and [g-32P] ATP (Perki-
nElmer, Boston, MA). Reactions were terminated and
analyzed as described elsewhere [43]. Incubation with
BI-D1870 was used to assess the specificity of Rsk activ-
ity assay.
Quantification of apoptosis
STHdhQ7/Q7 cells transfected with FL-17Q htt or FL-
75Q htt, with or without Rsk siRNAs, or Rsk DNA plas-
mid transfection or BI-D1870 treatment were processed
for immunocytochemistry against htt as described
above. Finally, cells were washed twice in PBS and
stained with Hoechst 33258 (1 μg/mL; Molecular
Probes, Inc, Eugene, OR) for 5 minutes. After washing
twice with PBS the coverslips were mounted with
mowiol. Nuclear DNA staining was observed with a
fluorescence microscope (Olympus). Transfected cells
were detected by the overexpression of htt respect to
non-transfected cells. Condensed or fragmented nuclei
were counted as apoptotic. At least 100 cells were evalu-
ated for each condition in each independent experiment.
Statistical analysis
Statistical analysis was performed by using the one- or
two-way analysis of variance (ANOVA) followed by
Bonferroni’s post-hoc test, or the unpaired Student’s t-
test, as appropriate and indicated in the figure legends.
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The analysis of Rsk distribution by immunocytochemical
staining was performed using the chi square. A value of
p < 0.05 was accepted as denoting statistical significance.
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